Literature DB >> 31983560

VA-Radiation Oncology Quality Surveillance Program.

Michael Hagan1, Rishabh Kapoor2, Jeff Michalski3, Howard Sandler4, Benjamin Movsas5, Indrin Chetty6, Brian Lally6, Ramesh Rengan6, Cliff Robinson6, Andreas Rimner6, Charles Simone6, Robert Timmerman6, Michael Zelefsky7, John DeMarco7, Daniel Hamstra7, Colleen Lawton7, Louis Potters7, Richard Valicenti7, Sasa Mutic3, Walter Bosch3, Christopher Abraham3, Douglas Caruthers3, Ryan Brame3, Jatinder R Palta2, William Sleeman8, Joseph Nalluri8.   

Abstract

PURPOSE: We sought to develop a quality surveillance program for approximately 15,000 US veterans treated at the 40 radiation oncology facilities at the Veterans Affairs (VA) hospitals each year. METHODS AND MATERIALS: State-of-the-art technologies were used with the goal to improve clinical outcomes while providing the best possible care to veterans. To measure quality of care and service rendered to veterans, the Veterans Health Administration established the VA Radiation Oncology Quality Surveillance program. The program carries forward the American College of Radiology Quality Research in Radiation Oncology project methodology of assessing the wide variation in practice pattern and quality of care in radiation therapy by developing clinical quality measures (QM) used as quality indices. These QM data provide feedback to physicians by identifying areas for improvement in the process of care and identifying the adoption of evidence-based recommendations for radiation therapy.
RESULTS: Disease-site expert panels organized by the American Society for Radiation Oncology (ASTRO) defined quality measures and established scoring criteria for prostate cancer (intermediate and high risk), non-small cell lung cancer (IIIA/B stage), and small cell lung cancer (limited stage) case presentations. Data elements for 1567 patients from the 40 VA radiation oncology practices were abstracted from the electronic medical records and treatment management and planning systems. Overall, the 1567 assessed cases passed 82.4% of all QM. Pass rates for QM for the 773 lung and 794 prostate cases were 78.0% and 87.2%, respectively. Marked variations, however, were noted in the pass rates for QM when tumor site, clinical pathway, or performing centers were separately examined.
CONCLUSIONS: The peer-review protected VA-Radiation Oncology Surveillance program based on clinical quality measures allows providers to compare their clinical practice to peers and to make meaningful adjustments in their personal patterns of care unobtrusively.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2020        PMID: 31983560     DOI: 10.1016/j.ijrobp.2019.08.064

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  Strategic Initiatives for Veterans with Lung Cancer.

Authors:  Drew Moghanaki; Michael Hagan
Journal:  Fed Pract       Date:  2020-08

2.  Automated data abstraction for quality surveillance and outcome assessment in radiation oncology.

Authors:  Rishabh Kapoor; William C Sleeman; Joseph J Nalluri; Paul Turner; Priyankar Bose; Andrii Cherevko; Sriram Srinivasan; Khajamoinuddin Syed; Preetam Ghosh; Michael Hagan; Jatinder R Palta
Journal:  J Appl Clin Med Phys       Date:  2021-06-08       Impact factor: 2.102

Review 3.  Quality indicators for radiation oncology.

Authors:  Susan V Harden; Kim-Lin Chiew; Jeremy Millar; Shalini K Vinod
Journal:  J Med Imaging Radiat Oncol       Date:  2022-03       Impact factor: 1.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.